Skip to main content
Top
Published in: Journal of Clinical Immunology 5/2011

01-10-2011

The Relationship Between Hypogammaglobulinemia, Monoclonal Gammopathy of Undetermined Significance and Humoral Immunodeficiency: a Case Series

Authors: Robert Marc Zemble, Patricia A. Takach, Arnold I. Levinson

Published in: Journal of Clinical Immunology | Issue 5/2011

Login to get access

Abstract

Hypogammaglobulinemia of the non-monoclonal immunoglobulin heavy chain classes has been reported in monoclonal gammopathy of undetermined significance (MGUS) patients. Whether low polyclonal immunoglobulin levels are associated with impaired specific antibody production and whether they represent a risk factor for the development of recurrent bacterial infections have not been established in this population. We determined the frequency of MGUS in patients referred to a tertiary care clinical immunology ambulatory care practice for evaluation of hypogammaglobulinemia, who were assessed for deficits in specific antibody production and the presence of recurrent infections. Of the 133 patients evaluated for hypogammaglobulinemia, 68 were screened for monoclonal gammopathy and 5 were found to have MGUS. Three had MGUS associated hypogammaglobulinemia in the absence of a defining primary immunodeficiency, one possibly had common variable immunodeficiency, and one had an uncertain diagnosis. Thus, MGUS may be uncovered in patients presenting with hypogammaglobulinemia even in those who lack an elevated serum level of IgG, IgM, or IgA.
Literature
1.
go back to reference Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med. 1978;64:814–26.PubMedCrossRef Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med. 1978;64:814–26.PubMedCrossRef
2.
go back to reference Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362–9.PubMedCrossRef Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362–9.PubMedCrossRef
3.
go back to reference Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–9.PubMedCrossRef Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–9.PubMedCrossRef
4.
go back to reference Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003; 121: 749–757. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003; 121: 749–757.
5.
go back to reference Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121–7.PubMedCrossRef Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121–7.PubMedCrossRef
6.
go back to reference Aguzzi F, Bergami MR, Gasparro C, Bellotti V, Merlini G. Occurrence of monoclonal components in general practice: clinical implications. Eur J Haematol. 1992;48:192–5.PubMedCrossRef Aguzzi F, Bergami MR, Gasparro C, Bellotti V, Merlini G. Occurrence of monoclonal components in general practice: clinical implications. Eur J Haematol. 1992;48:192–5.PubMedCrossRef
7.
go back to reference Axelsson U, Bachmann R, Hallen J. Frequency of pathological proteins (M-components) om 6,995 sera from an adult population. Acta Med Scand. 1966;179:235–47.PubMedCrossRef Axelsson U, Bachmann R, Hallen J. Frequency of pathological proteins (M-components) om 6,995 sera from an adult population. Acta Med Scand. 1966;179:235–47.PubMedCrossRef
8.
go back to reference Carrell RW, Colls BM, Murray JT. The significance of monoclonal gammopathy in a normal population. Aust N Z J Med. 1971;1:398–401.PubMedCrossRef Carrell RW, Colls BM, Murray JT. The significance of monoclonal gammopathy in a normal population. Aust N Z J Med. 1971;1:398–401.PubMedCrossRef
9.
go back to reference Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med. 1998;104:439–44.PubMedCrossRef Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med. 1998;104:439–44.PubMedCrossRef
10.
go back to reference Hallen J. Frequency of "abnormal" serum globulins (M-components) in the aged. Acta Med Scand. 1963;173:737–44.PubMedCrossRef Hallen J. Frequency of "abnormal" serum globulins (M-components) in the aged. Acta Med Scand. 1963;173:737–44.PubMedCrossRef
11.
go back to reference Kyle RA, Finkelstein S, Elveback LR, Kurland LT. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood. 1972;40:719–24.PubMed Kyle RA, Finkelstein S, Elveback LR, Kurland LT. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood. 1972;40:719–24.PubMed
12.
go back to reference Malacrida V, De Francesco D, Banfi G, Porta FA, Riches PG. Laboratory investigation of monoclonal gammopathy during 10 years of screening in a general hospital. J Clin Pathol. 1987;40:793–7.PubMedCrossRef Malacrida V, De Francesco D, Banfi G, Porta FA, Riches PG. Laboratory investigation of monoclonal gammopathy during 10 years of screening in a general hospital. J Clin Pathol. 1987;40:793–7.PubMedCrossRef
13.
go back to reference Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistere, France. J Clin Pathol. 1982;35:63–8.PubMedCrossRef Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistere, France. J Clin Pathol. 1982;35:63–8.PubMedCrossRef
14.
go back to reference Vladutiu AO. Prevalence of M-proteins in serum of hospitalized patients. Physicians’ response to finding M-proteins in serum protein electrophoresis. Ann Clin Lab Sci. 1987;17:157–61.PubMed Vladutiu AO. Prevalence of M-proteins in serum of hospitalized patients. Physicians’ response to finding M-proteins in serum protein electrophoresis. Ann Clin Lab Sci. 1987;17:157–61.PubMed
15.
go back to reference Baldini L, Guffanti A, Cesana BM, Colombi M, Chiorboli O, Damilano I, et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood. 1996;87:912–8.PubMed Baldini L, Guffanti A, Cesana BM, Colombi M, Chiorboli O, Damilano I, et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood. 1996;87:912–8.PubMed
16.
go back to reference Blade J, Lopez-Guillermo A, Rozman C, Cervantes F, Salgado C, Aguilar JL, et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol. 1992;81:391–4.PubMedCrossRef Blade J, Lopez-Guillermo A, Rozman C, Cervantes F, Salgado C, Aguilar JL, et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol. 1992;81:391–4.PubMedCrossRef
17.
go back to reference Carter A, Tatarsky I. The physiopathological significance of benign monoclonal gammopathy: a study of 64 cases. Br J Haematol. 1980;46:565–74.PubMedCrossRef Carter A, Tatarsky I. The physiopathological significance of benign monoclonal gammopathy: a study of 64 cases. Br J Haematol. 1980;46:565–74.PubMedCrossRef
18.
go back to reference Gregersen H, Mellemkjaer L, Ibsen JS, Dahlerup JF, Thomassen L, Sorensen HT. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica. 2001;86:1172–9.PubMed Gregersen H, Mellemkjaer L, Ibsen JS, Dahlerup JF, Thomassen L, Sorensen HT. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica. 2001;86:1172–9.PubMed
19.
go back to reference Vuckovic J, Ilic A, Knezevic N, Marinkovic M, Zemunik T, Dubravcic M. Prognosis in monoclonal gammopathy of undetermined significance. Br J Haematol. 1997;97:649–51.PubMedCrossRef Vuckovic J, Ilic A, Knezevic N, Marinkovic M, Zemunik T, Dubravcic M. Prognosis in monoclonal gammopathy of undetermined significance. Br J Haematol. 1997;97:649–51.PubMedCrossRef
20.
go back to reference Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002;20:1625–34.PubMedCrossRef Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002;20:1625–34.PubMedCrossRef
21.
go back to reference Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 2008;111:3388–94.PubMedCrossRef Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 2008;111:3388–94.PubMedCrossRef
22.
go back to reference Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immun. 2005;94:S1–S63.CrossRef Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immun. 2005;94:S1–S63.CrossRef
23.
go back to reference Paris K, Sorensen RU. Assessment and clinical interpretation of polysaccharide antibody responses. Ann Allergy Asthma Immun. 2007;99:462–4.CrossRef Paris K, Sorensen RU. Assessment and clinical interpretation of polysaccharide antibody responses. Ann Allergy Asthma Immun. 2007;99:462–4.CrossRef
24.
go back to reference Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS. Common variable immunodeficiency: a new look at an old disease. Lancet. 2008;372:489–502.PubMedCrossRef Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS. Common variable immunodeficiency: a new look at an old disease. Lancet. 2008;372:489–502.PubMedCrossRef
25.
go back to reference Kyrtsonis MC, Mouzaki A, Maniatis A. Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM). Med Oncol. 1999;16:73–7.PubMedCrossRef Kyrtsonis MC, Mouzaki A, Maniatis A. Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM). Med Oncol. 1999;16:73–7.PubMedCrossRef
26.
go back to reference Broder S, Humphrey R, Durm M, Blackman M, Meade B, Goldman C, et al. Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma: role of suppressor cells. N Engl J Med. 1975;293:887–92.PubMedCrossRef Broder S, Humphrey R, Durm M, Blackman M, Meade B, Goldman C, et al. Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma: role of suppressor cells. N Engl J Med. 1975;293:887–92.PubMedCrossRef
27.
go back to reference Kawano M, Iwato K, Asaoku H, Tanabe O, Tanaka H, Ishikawa H, et al. Altered cytokine activities are related to the suppression of synthesis of normal immunoglobulin in multiple myeloma. Am J Hematol. 1989;30:91–6.PubMedCrossRef Kawano M, Iwato K, Asaoku H, Tanabe O, Tanaka H, Ishikawa H, et al. Altered cytokine activities are related to the suppression of synthesis of normal immunoglobulin in multiple myeloma. Am J Hematol. 1989;30:91–6.PubMedCrossRef
28.
go back to reference Kennard J, Zolla-Pazner S. Origin and function of suppressor macrophages in myeloma. J Immunol. 1980;124:268–73.PubMed Kennard J, Zolla-Pazner S. Origin and function of suppressor macrophages in myeloma. J Immunol. 1980;124:268–73.PubMed
29.
go back to reference Kyrtsonis MC, Repa C, Dedoussis GV, Mouzaki A, Simeonidis A, Stamatelou M, et al. Serum transforming growth factor-beta 1 is related to the degree of immunoparesis in patients with multiple myeloma. Med Oncol. 1998;15:124–8.PubMedCrossRef Kyrtsonis MC, Repa C, Dedoussis GV, Mouzaki A, Simeonidis A, Stamatelou M, et al. Serum transforming growth factor-beta 1 is related to the degree of immunoparesis in patients with multiple myeloma. Med Oncol. 1998;15:124–8.PubMedCrossRef
30.
go back to reference Massaia M, Borrione P, Attisano C, Barral P, Beggiato E, Montacchini L, et al. Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood. 1995;85:3679–87.PubMed Massaia M, Borrione P, Attisano C, Barral P, Beggiato E, Montacchini L, et al. Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood. 1995;85:3679–87.PubMed
31.
go back to reference Rawstron AC, Davies FE, Owen RG, English A, Pratt G, Child JA, et al. B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors. Br J Haematol. 1998;100:176–83.PubMedCrossRef Rawstron AC, Davies FE, Owen RG, English A, Pratt G, Child JA, et al. B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors. Br J Haematol. 1998;100:176–83.PubMedCrossRef
32.
go back to reference Tsujimoto T, Lisukov IA, Huang N, Mahmoud MS, Kawano MM. Plasma cells induce apoptosis of pre-B cells by interacting with bone marrow stromal cells. Blood. 1996;87:3375–83.PubMed Tsujimoto T, Lisukov IA, Huang N, Mahmoud MS, Kawano MM. Plasma cells induce apoptosis of pre-B cells by interacting with bone marrow stromal cells. Blood. 1996;87:3375–83.PubMed
33.
go back to reference Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92:34–48.PubMedCrossRef Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92:34–48.PubMedCrossRef
34.
go back to reference Mellemkjaer L, Hammarstrom L, Andersen V, Yuen J, Heilmann C, Barington T, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol. 2002;130:495–500.PubMedCrossRef Mellemkjaer L, Hammarstrom L, Andersen V, Yuen J, Heilmann C, Barington T, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol. 2002;130:495–500.PubMedCrossRef
Metadata
Title
The Relationship Between Hypogammaglobulinemia, Monoclonal Gammopathy of Undetermined Significance and Humoral Immunodeficiency: a Case Series
Authors
Robert Marc Zemble
Patricia A. Takach
Arnold I. Levinson
Publication date
01-10-2011
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 5/2011
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-011-9548-0

Other articles of this Issue 5/2011

Journal of Clinical Immunology 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine